Skip to main content
SpringerLink
Log in

Efficacy of long-term lanreotide treatment in patients with acromegaly

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5 ± 13.9 years) with acromegaly treated with lanreotide in nine different centers. Mean tumor diameter was 20 ± 13 mm; mean basal levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) were 21.3 ± 26.3 and 579 ± 177 μg/l, respectively. The primary mode of treatment was surgery in 70% of patients. Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide at another treatment stage. Primary therapy with lanreotide was administered in five patients. Maximal monthly dose of lanreotide Autogel (n = 44) was 60 mg in 45%, 90 mg in 26%, 120 mg in 21% and 180 mg in 8%. During 36 months of lanreotide treatment, mean IGF-I levels decreased from 443 ± 238 to 276 ± 147 μg/l (P < 0.001), and mean GH levels, from 5.2 ± 6.4 to 3.2 ± 3.0 μg/l (P < 0.001). IGF-I levels normalized in 51% of patients and decreased by >50% towards normal in 32%; the normalization rate was higher in women (65%) than men (33%, P = 0.04). Safe random GH levels (≤2 μg/l) were achieved in 49% of patients. Both IGF-I normalization and safe GH levels were reached in 32% of the cohort. Lanreotide is an effective treatment for active acromegaly. Female sex was associated with higher rates of IGF-I normalization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674. doi:10.1210/jc.2003-031199

    Article  CAS  PubMed  Google Scholar 

  2. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081–4086. doi:10.1210/jc.2004-1381

    Article  PubMed  CAS  Google Scholar 

  3. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95–102. doi:10.1111/j.1365-2265.1994.tb03789.x

    Article  CAS  Google Scholar 

  4. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789–2796. doi:10.1210/jc.2003-032041

    Article  CAS  PubMed  Google Scholar 

  5. Swearingen B, Barker FGII, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419–3426. doi:10.1210/jc.83.10.3419

    Article  CAS  PubMed  Google Scholar 

  6. Melmed S (2006) Acromegaly. N Engl J Med 355:2558–2573. doi:10.1056/NEJMra062453

    Article  CAS  PubMed  Google Scholar 

  7. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76:721–727. doi:10.1210/jc.76.3.721

    Article  CAS  PubMed  Google Scholar 

  8. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Lauberg P, Pico AH, Valimaki M, Zgliczynsk W (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99–104. doi:10.1210/jc.87.1.99

    Article  CAS  PubMed  Google Scholar 

  9. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, Lamberts SW, Marbach P, Orskov H, Pagani G, Sheppard M, Simionescu L (1996) Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 45:67–71. doi:10.1016/S0026-0495(96)90087-6

    Article  CAS  PubMed  Google Scholar 

  10. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013–3018. doi:10.1210/jc.87.7.3013

    Article  CAS  PubMed  Google Scholar 

  11. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64:209–214. doi:10.1111/j.1365-2265.2006.02450.x

    Article  CAS  Google Scholar 

  12. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Acromegaly treatment consensus workshop participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058. doi:10.1210/jc.2002-011841

    Article  CAS  PubMed  Google Scholar 

  13. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529. doi:10.1210/jc.85.2.526

    Article  CAS  PubMed  Google Scholar 

  14. Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, Arosio M (2005) Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 90:1377–1382. doi:10.1210/jc.2004-1974

    Article  CAS  PubMed  Google Scholar 

  15. Schonbrunn A (1999) Somatostatin receptors present knowledge and future directions. Ann Oncol 10(Suppl 2):S17–S21. doi:10.1023/A:1027392228418

    Article  PubMed  Google Scholar 

  16. Shimon I, Melmed S (1997) Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 155(Suppl 1):S3–S6 (discussion S7–S8)

    CAS  PubMed  Google Scholar 

  17. Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1–5) in pituitary tumors. Life Sci 56:333–342. doi:10.1016/0024-3205(94)00956-2

    Article  CAS  PubMed  Google Scholar 

  18. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386–1392. doi:10.1210/jc.80.4.1386

    Article  CAS  PubMed  Google Scholar 

  19. Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724–729. doi:10.1210/jc.79.3.724

    Article  CAS  PubMed  Google Scholar 

  20. Greenman Y, Melmed S (1994) Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398–403. doi:10.1210/jc.78.2.398

    Article  CAS  PubMed  Google Scholar 

  21. Heron I, Thomas F, Dero M, Poutrain JR, Henane S, Catus F, Kuhn JM (1993) Treatment of acromegaly with sustained-release lanreotide, a new somatostatin analog. Presse Med 22:526–531

    CAS  PubMed  Google Scholar 

  22. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC (1995) Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80:3267–3272. doi:10.1210/jc.80.11.3267

    Article  CAS  PubMed  Google Scholar 

  23. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R (2003) Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258–5265. doi:10.1210/jc.2003-030266

    Article  CAS  PubMed  Google Scholar 

  24. Ronchi CL, Boschetti M, Degli Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M (2007) Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicenter longitudinal study. Clin Endocrinol (Oxf) 67:512–519

    CAS  Google Scholar 

  25. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G (2000) Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 85:4099–4103. doi:10.1210/jc.85.11.4099

    Article  CAS  PubMed  Google Scholar 

  26. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465–4473. doi:10.1210/jc.2005-0260

    Article  CAS  PubMed  Google Scholar 

  27. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 8:2957–2968. doi:10.1210/jc.2008-0027

    Article  CAS  Google Scholar 

  28. Chanson P, Borson-Chazot F, Kuhn J-M, Blumberg J, Maisonobe P, Delemer B (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69:299–305. doi:10.1111/j.1365-2265.2008.03208.x

    Article  CAS  Google Scholar 

  29. Bates AS, Evans AJ, Jones P, Clayton RN (1995) Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxf) 42:417–423. doi:10.1111/j.1365-2265.1995.tb02651.x

    Article  CAS  Google Scholar 

  30. Wass JAH (1997) Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly. J Endocrinol 155(Suppl 1):S17–S19

    CAS  PubMed  Google Scholar 

  31. Freda PU, Post KD, Powell JS, Wardlaw SL (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83:3808–3816. doi:10.1210/jc.83.11.3808

    Article  CAS  PubMed  Google Scholar 

  32. Growth Hormone Research Society, Pituitary Society (2004) Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the growth hormone research society and the pituitary society. J Clin Endocrinol Metab 89:3099–3102. doi:10.1210/jc.2003-031138

    Article  CAS  Google Scholar 

  33. Alexopoulou O, Bex M, Abs R, T’Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324–1330. doi:10.1210/jc.2007-2104

    Article  CAS  PubMed  Google Scholar 

  34. Freda PU (2000) Advances in the diagnosis of acromegaly. Endocrinologist 10:237–244. doi:10.1097/00019616-200010040-00005

    Article  Google Scholar 

  35. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89–95. doi:10.1530/EJE-08-0267

    Article  CAS  PubMed  Google Scholar 

  36. Parkinson C, Ryder WDJ, Trainer PJ (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86:5240–5244. doi:10.1210/jc.86.11.5240

    Article  CAS  PubMed  Google Scholar 

  37. Weissberger AJ, Ho KK, Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72:374–381

    Article  CAS  PubMed  Google Scholar 

  38. Engstrom BE, Burman P, Karlsson FA (2002) Men with acromegaly need higher doses of octreotide than women. Clin Endocrinol (Oxf) 56:73–77. doi:10.1046/j.0300-0664.2001.01440.x

    Article  CAS  Google Scholar 

  39. Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G (2005) Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 63:342–349. doi:10.1111/j.1365-2265.2005.02351.x

    Article  CAS  Google Scholar 

  40. Dobrashian RD, O’Halloran DJ, Hunt A, Beardwell CG, Shalet SM (1993) Relationships between insulin-like growth factor-1 levels and growth hormone concentration during diurnal profiles and following oral glucose in acromegaly. Clin Endocrinol (Oxf) 38:589–593. doi:10.1111/j.1365-2265.1993.tb02139.x

    Article  CAS  Google Scholar 

  41. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91:2112–2118. doi:10.1210/jc.2005-2110

    Article  CAS  PubMed  Google Scholar 

  42. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jimenez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM (2000) Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 53:577–586. doi:10.1046/j.1365-2265.2000.01134.x

    Article  CAS  Google Scholar 

  43. Turner HE, Vadivale A, Keenan J, Wass JA (1999) A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 51:275–280. doi:10.1046/j.1365-2265.1999.00853.x

    Article  CAS  Google Scholar 

  44. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G (1999) A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 141:267–271. doi:10.1530/eje.0.1410267

    Article  CAS  PubMed  Google Scholar 

  45. van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frolich M, Smit JW, Corssmit EP, Roelfsema F, Pereira AM (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 150:489–495. doi:10.1530/eje.0.1500489

    Article  PubMed  Google Scholar 

  46. Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA, James RA (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 150:473–480. doi:10.1530/eje.0.1500473

    Article  CAS  PubMed  Google Scholar 

  47. Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abstract R, Maiter D (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 151:317–324. doi:10.1530/eje.0.1510317

    Article  CAS  PubMed  Google Scholar 

  48. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65–71. doi:10.1046/j.0300-0664.2001.01438.x

    Article  CAS  Google Scholar 

  49. Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J (2005) Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 113:139–144. doi:10.1055/s-2005-837520

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was partially supported by a grant from Medison Pharma, Israel. We thank Ms. Gloria Ginzach for her assistance in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Unit of Endocrinology & Diabetes, Hillel Yaffe Medical Center, Hadera, Israel

    Yoel Toledano

  2. Institute of Endocrinology, Rabin Medical Center, Beilinson Campus, 49100, Petah Tiqva, Israel

    Liat Rot, Gloria Tsvetov, Carlos Benbassat & Ilan Shimon

  3. Institute of Endocrinology, Metabolism and Hypertension, Sourasky Medical Center, Tel Aviv, Israel

    Yona Greenman

  4. Maccabi Health Services, Haifa, Israel

    Sophia Orlovsky & Hadassah Guttmann

  5. Clalit Health Services, Haifa, Israel

    Yulia Pauker, Orit Bardicef & Michal Gershinsky

  6. Maccabi Health Services, Bnei-Brak, Israel

    Achia Eliash

  7. Clalit Health Services, Jerusalem, Israel

    Ofa Makhoul & Odile Cohen-Ouaqnine

  8. Clalit Health Services, Tel Aviv, Israel

    Mazal Sapir

  9. Department of Medicine A, Sheba Medical Center, Tel Hashomer, Israel

    David Olchovsky

  10. Endocrine Unit, Sapir Medical Center, Kfar Saba, Israel

    Rosane Ness-Abramof

  11. Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Haifa, Israel

    Zaina Adnan

  12. Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel

    Jacob Ilany

  13. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Yona Greenman, David Olchovsky, Gloria Tsvetov, Carlos Benbassat & Ilan Shimon

Authors
  1. Yoel Toledano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liat Rot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yona Greenman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sophia Orlovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yulia Pauker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Olchovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Achia Eliash
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Orit Bardicef
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ofa Makhoul
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gloria Tsvetov
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michal Gershinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Odile Cohen-Ouaqnine
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rosane Ness-Abramof
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Zaina Adnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jacob Ilany
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hadassah Guttmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Mazal Sapir
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Carlos Benbassat
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Ilan Shimon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ilan Shimon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toledano, Y., Rot, L., Greenman, Y. et al. Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary 12, 285–293 (2009). https://doi.org/10.1007/s11102-009-0172-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-009-0172-4

Keywords

Search

Navigation